Artificial Hormones Can Cause Breast Cancer!.htm

[Guest guest]

Artificial Hormones Can Cause Breast Cancer!-

http://www.oralchelation.com/calcium/footbone/fbartifi.htm -

Artificial Hormones Can Cause Breast Cancer

 

The Reference Was

One of the few accepted medial treatments for osteoporosis is, in fact,

artificial hormone treatment with estrogen. Unfortunately prolonged use of

the artificial substance seems to lead to higher rates of breast cancer.

Return To The Article

 

 

There are several actual scientific studies, abstracts, reproduced below.

For a popular story on this, here is one example:

 

Hormone Therapy Raises Breast-Cancer Risk, Medical Tribune News Service,

June 14, 1995, by Theresa Tamkins.

Here are some lines from the reports below:

" The median duration of treatment was 12 weeks and all patients stopped

because of progressive disease with or without toxicity. "

" We conclude that hormone replacement increases the endometrial-cancer risk

after unopposed estrogens and the breast-cancer risk-notably after

estrogen-progestin combined therapy-and tentatively suggest that it exerts a

protective effect against colon and liver cancer risks. "

" Women in various risk groups, such as those at risk for coronary artery

disease, osteoporosis, or breast cancer, must consider the risk-to-benefit

ratio for their own individual circumstances. "

" Postmenopausal women who take estrogens for an extended period of time

(e.g., a decade or more) incur a sharply increased risk of cancer of the

endometrium. This is largely abated by use of a progestogen for at least 10

days per month. "

And some with good news:

" The role of estrogen therapy in the risk of breast cancer has been a

concern for both physicians and patients. There is some evidence that women

taking estrogen who develop breast cancer have a better prognosis. "

Return To The Article

 

 

 

 

Title

Health consequences of short- and long-term postmenopausal hormone therapy.

Author

Weiss NS

Address

University of Washington, Seattle 98195, USA. nweiss

Source

Clin Chem, 1996 Aug, 42:8 Pt 2, 1342-4

Abstract

Some women take an estrogen preparation for as long as several years to ease

symptoms of the menopause. Such women appear to have little or no alteration

in their risk of endometrial cancer, especially if they are also taking a

progestogen, and no alteration in their risk of breast cancer. Similarly,

the incidence of fractures is unaffected by relatively short-term hormone

use. The risk of ischemic heart disease also is reduced among women who

currently take estrogens (with or without a progestogen), but the influence

of duration of use on this association is uncertain. Postmenopausal women

who take estrogens for an extended period of time (e.g., a decade or more)

incur a sharply increased risk of cancer of the endometrium. This is largely

abated by use of a progestogen for at least 10 days per month. Such

long-term estrogen use, whether accompanied by a progestogen or not, may

increase the risk of breast cancer slightly, but this is an area of great

controversy, at present unresolved. The incidence of both myocardial

infarction and fracture is substantially reduced in long-term users of

menopausal hormones.

Language of Publication

LA=ENG

Unique Identifier

96330280

MeSH Heading (Major)

Estrogen Replacement Therapy|*/AE; Postmenopause|*

MeSH Heading

Breast Neoplasms|CI; Endometrial Neoplasms|CI/PC; Estrogens|AD/AE/TU;

Female; Human; Progesterone|AD/TU

Publication Type

JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

ISSN

0009-9147

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Estrogens); 57-83-0 (Progesterone)

Return To The Article

 

 

 

Title

Cancer incidence and mortality in women receiving estrogen and

estrogen-progestin replacement therapy--long-term follow-up of a Swedish

cohort.

Author

Persson I; Yuen J; Bergkvist L; Schairer C

Address

Department of Cancer Epidemiology, University Hospital, Uppsala, Sweden.

Source

Int J Cancer, 1996 Jul 29, 67:3, 327-32

Abstract

We analyzed cancer incidence and mortality in a cohort of 22,597 Swedish

women who were prescribed replacement hormones. After 13 years of follow-up

in national registries, 2,330 incident cancer cases and 848 cancer deaths

were observed. Overall, our results were reassuring since incidence rate

ratios (SIRs) for 16 cancer sites and mortality ratios (SMRs) for all 10

examined sites were at, or lower than, unity. However, we found that

exposure to an estrogen-progestin combined brand was associated with an

increasing relative risk of breast cancer with follow-up time, the SIR

reaching 1.4 (95% CI 1.1-1.8) after 10 years of follow-up. The relative risk

of endometrial cancer was substantially increased, with the highest SIR of

5.0 (95% CI 1.6-5.9) in women prescribed estrogens alone, whereas those

given an estrogen-progestin combination showed no elevation in risk. The

risk estimates for liver and biliary tract cancers and for colon cancer were

reduced by about 40%, notably in women prescribed the estradiol-progestin

compound. Further detailed analyses revealed no evidence of adverse or

protective effects on the risk of ovarian, uterine cervical, vulvar/vaginal,

rectal, pancreatic, renal, lung, thyroid and other endocrine cancers, brain

tumors, malignant melanoma or other skin cancers. Hormone replacement

therapy was not associated with an increase in mortality for any cancer

site, at this time of follow-up. For breast and endometrial cancers, SMRs

were below baseline but tended to increase with follow-up time. We conclude

that hormone replacement increases the endometrial-cancer risk after

unopposed estrogens and the breast-cancer risk-notably after

estrogen-progestin combined therapy-and tentatively suggest that it exerts a

protective effect against colon and liver cancer risks.

Language of Publication

LA=ENG

Unique Identifier

96321015

MeSH Heading (Major)

Estrogen Replacement Therapy|*AE; Neoplasms|*CI/*EP/MO

MeSH Heading

Aged; Breast Neoplasms|CI/EP/MO; Cohort Studies; Comparative Study;

Estradiol|AE/TU; Estrogens, Conjugated|AE/TU; Female; Follow-Up Studies;

Genital Neoplasms, Female|CI/EP/MO; Human; Incidence; Middle Age;

Progestational Hormones|AE/TU; Registries; Support, Non-U.S. Gov't; Support,

U.S. Gov't, P.H.S.; Sweden|EP; Time Factors

Publication Type

JOURNAL ARTICLE

ISSN

0020-7136

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Estrogens, Conjugated); 0 (Progestational Hormones); 50-28-2 (Estradiol)

Return To The Article

 

 

 

Title

Current concepts in postmenopausal hormone replacement therapy.

Author

Mayeaux EJ Jr; Johnson C

Address

Department of Family Medicine, Lousiana State University Medical Center,

Shreveport, USA.

Source

J Fam Pract, 1996 Jul, 43:1, 69-75

Abstract

As more women are living longer, there is an increasing need for women to

discuss hormone replacement therapy (HRT) with their physicians. This task

is complicated by areas of scientific uncertainty and evolving data

concerning the risks and benefits of HRT. Benefits of HRT that are supported

by strong scientific evidence include relief from menopausal symptoms such

as hot flashes, prevention of osteoporosis, cardioprotective effects, relief

of urogenital atrophy, and decreased urinary incontinence. Benefits

supported by observational evidence include improvement of emotional

lability and depression, improved sense of well-being in patients with

rheumatoid arthritis, increased dermal and total skin thickness, improved

verbal memory skills, and decreased risk of colon cancer. Risks to consider

include a possible increase in the incidence of breast cancer and an

increase in endometrial cancer in women who have an intact uterus and do not

receive a progestin. Women in various risk groups, such as those at risk for

coronary artery disease, osteoporosis, or breast cancer, must consider the

risk-to-benefit ratio for their own individual circumstances.

Language of Publication

LA=ENG

Unique Identifier

96315595

MeSH Heading (Major)

Estrogen Replacement Therapy|*/AE; Estrogens|AD/AE/*TU

MeSH Heading

Breast Neoplasms|CI; Female; Human; Patient Selection; Progesterone|TU; Risk

Factors

Publication Type

JOURNAL ARTICLE REVIEW REVIEW LITERATURE

ISSN

0094-3509

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Estrogens); 57-83-0 (Progesterone)

Return To The Article

 

 

 

Title

Hormone replacement therapy and breast cancer risk.

Author

Gambrell RD Jr

Address

Department of Physiology and Endocrinology, Medical College of Georgia,

Augusta, USA.

Source

Arch Fam Med, 1996 Jun, 5:6, 341-8

Abstract

The role of estrogen therapy in the risk of breast cancer has been a concern

for both physicians and patients. There is some evidence that women taking

estrogen who develop breast cancer have a better prognosis. During 8 to 18

years of follow-up of 256 postmenopausal women with breast cancer from our

hospital, median survival time was 84 months for those who never used

estrogen, 80 months for past users, and 143 months for current users. More

than 50 studies have shown that there is no increased risk of breast cancer

even with long-term estrogen use, while some studies suggest an increased

risk. Several studies indicate that when progestogens are added to estrogen

therapy, there is a significant reduction in the risk of breast carcinoma.

Indirect evidence is accumulating to show why added progestogen should

decrease the risk of breast cancer. Preliminary studies further indicate

that estrogen therapy, which has been contraindicated in breast cancer

survivors in the past, may be safe, and added progestogens may decrease

recurrences and deaths. Some medical oncologists and surgeons now advocate

estrogen use in women with previous carcinoma of the breast.

Language of Publication

LA=ENG

Unique Identifier

96240201

MeSH Heading (Major)

Breast Neoplasms|CH/*CI/MO; Estrogen Replacement Therapy|*/AE

MeSH Heading

Adolescence; Adult; Aged; Aged, 80 and over; Clinical Trials; Comparative

Study; Estrogens|AD/AE; Ethinyl Estradiol|AD/AE; Female; Follow-Up Studies;

Human; Lymphatic Metastasis; Meta-Analysis; Middle Age; Multicenter Studies;

Postmenopause; Pregnancy; Progestational Hormones|AD/AE; Receptors,

Estradiol|AN; Receptors, Progesterone|AN; Risk Factors; Time Factors

Publication Type

JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL

ISSN

1063-3987

Country of Publication

UNITED STATES

CAS Registry/EC Number

0 (Estrogens); 0 (Progestational Hormones); 0 (Receptors, Estradiol); 0

(Receptors, Progesterone); 57-63-6 (Ethinyl Estradiol)

 

 

 

Title

Hormone replacement therapy as treatment of breast cancer--a phase II study

of Org OD 14 (tibilone).

Author

O'Brien M; Montes A; Powles TJ

Address

Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK.

Source

Br J Cancer, 1996 May, 73:9, 1086-8

Abstract

Org OD 14 (tibilone) is a synthetic steroid, designed to combine the

favourable effects of oestrogens, progestagens and androgens into a single

substance for use as hormone replacement therapy (HRT). Given its

antiovulatory properties, the ability to control menopausal symptoms and

blocking action on progesterone receptors, Org OD 14 was considered as an

agent with potential anti-cancer activity while at the same time helping

existing menopausal symptoms. In this phase II study, 14 post-menopausal

women with advanced or metastatic breast cancer, who had failed on

tamoxifen, were treated with Org OD 14. The median duration of treatment was

12 weeks and all patients stopped because of progressive disease with or

without toxicity. Vaginal bleeding occurred in four patients, three of whom

had recently stopped tamoxifen. One response was seen: an 82-year-old

patient had a partial response in an axillary soft tissue mass, improvement

in liver function tests and an improvement in her performance status that

lasted over 6 months. One patient with progressive disease on Org OD 14

improved on stopping the drug. In view of the vaginal bleeding, Org OD 14

should not be given to patients who have recently stopped tamoxifen.

Language of Publication

LA=ENG

Unique Identifier

96210992

MeSH Heading (Major)

Antineoplastic Agents, Hormonal|AE/*TU; Breast Neoplasms|*DT/PA; Estrogen

Replacement Therapy|*; Norpregnenes|AE/*TU

MeSH Heading

Adult; Aged; Aged, 80 and over; Female; Human; Middle Age; Neoplasm

Metastasis; Neoplasm Staging; Patient Compliance; Poisson Distribution;

Receptors, Estrogen|AN; Support, Non-U.S. Gov't

Publication Type

CLINICAL TRIAL CLINICAL TRIAL, PHASE II JOURNAL ARTICLE

ISSN

0007-0920

Country of Publication

ENGLAND

CAS Registry/EC Number

0 (Antineoplastic Agents, Hormonal); 0 (Norpregnenes); 0 (Receptors,

Estrogen); 5630-53-5 (tibolone)

Return To The Article

 

 

 

Home Page -- Vibrant Life Web Site Navigation Bar

OC HistoryOral ChelationTestimonials

Family Of Three Oral Chelation FormulasLife Glow BasicLife Glow Basic

Ingredient List

Life Glow PlusLife Glow Plus Ingredient ListAmerican Heart Association --

Lies

Super Life GlowSuper Life Glow Ingredient ListFAQ

All ProductsShopping Cart Order SectionResearch

Taheebo Life TeaWitch Doctors Versus HarvardMSM Sulfur

CalciumHow Bones GrowColloidal Minerals

Jean RossPhilosophyThe Wednesday Letter

Arthritis & James Coburn's Use Of MSMKarl Loren Viewpoints News And

Announcements

Dr. Flanagan's Microhydrin500 Page Book On Heart DiseaseColostrum & Transfer

Factor

GermaniumWeb StatsBulk MSM

Main Section TOCSearch All 4,000 PagesHeart Disease & Bypass Surgery

Karl Loren's DietGuaranteeLocal Section Help Page

Write To Karl Loren -- He Pledges To Answer EVERY Personal Message,

Personally. Click here or on his name in the box below.

 

I promise to answer your message -- click here to send me a personal

message

 

Dear Karl,

 

 

 

 

 

 

 

Search Tips

 

Search oralchelation.com The Vibrant Life Web Site

This Web Site

Other Web Sites Authored by Karl Loren:

Search karlloren.com

Search oralchelation.net Karl's Book: Life Flow One

Search bulkmsm.com Bulk MSM

Search supercolostrum.com Transfer Factor

Search insteadof.com

Search heart-disease-bypass-surgery.com New Site For Heart Disease

Search WWW

 

 

SUBSCRIBE: The Wednesday Letter is a free electronic monthly newsletter

written and published by Karl Loren. You can view more than 30 back issues

of this publication by clicking here. The Wednesday Letter subscription

list is maintained on a secure server, no name is ever given or sold to

anyone, and it is never used except for this Newsletter. It is

automatically published on the Tuesday night just before the first Wednesday

of every month. You can to this free monthly electronic letter by

entering your eMail address and name below. You will then automatically

receive a request for confirmation, sent to whatever address you have

entered. If you do NOT receive this confirmation request, then you will not

be d. There may have been an error with your address and you

should resubmit. The letter is never sent twice to the same address -- so

you do not have to worry about a duplicate subscription. When you receive

this confirmation request you must reply to it, or your subscription will

not become active. No one can your name, and address, without you

being notified, and if you get an unwanted notice of subscription you only

need to DO NOTHING and the subscription will NOT be active.

 

 

 

Email: Name:

 

 

 

 

 

ALTERNATIVE: You can also by CLICKING HERE. You will arrive at a

page on the SparkList web site -- a page specifically for entering a

subscription to The Wednesday Letter.

REMOVAL: You can remove yourself from the subscription list in several

different ways. Click here to read about this entire newsletter system.

Every edition of The Wednesday Letter is delivered to your address with YOUR

name and address in view on the letter, with a link that allows you to

remove THAT name from the subscription list. If you try to send this

removal message from an address different from the one you used to send in

your original confirmation, then you will get a warning notice first, sent

to the subscription address, asking you to confirm that you want to be

removed from the list -- by replying to THAT request for confirmation, you

will then be automatically removed. Thus, no one else can you,

from some other computer, without your knowledge. But, if you send in the

notice from the same machine used to receive the Letter, then

the removal from the subscription list is automatic.

Personal Message: If you send a personal message to Karl Loren, you will

receive a personal reply from him. Karl pledges to answer personally every

personal message he receives. Only your name and eMail address are

required. However, if you provide your mail address, we will send you free

information including our free catalog and a cassette tape lecture by Karl

Loren about heart disease, no charge, by mail, even if outside the US. You

can select particular information you would like to receive, along with the

free cassette tape and catalog.

You can reach Vibrant Life in many ways, including by mail to Vibrant Life,

1831 N. Bel Aire Drive, Burbank, CA 91504. Within the US and Canada, use

the toll free number: (800) 523-4521, the local number: (818) 558-1799,

the FAX: (818) 558-7299, eMail to jean or any one of the

hundreds of message forms throughout the web site. Vibrant Life normally

ships the same day we get an order. There are message forms on each of the

4000+ pages on this site where you can communicate with Vibrant Life. Check

out our companion site, at: http://www.oralchelation.net where Karl's 2000

page book is published. Karl Loren is the author and webmaster for this

BOOK, as well as for another web site about ORAL CHELATION. He is also the

author of a web site about the immune system and COLOSTRUM, as well as

FIBROMYALGIA. His personal philosophical articles are at PHILOSOPHY, while

his herbal cigarette web site is at INSTEADOF.

October 09, 2001 02:59 PM by Vibrant Life, ALL RIGHTS RESERVED.

Permission is granted for non-commercial downloading, copying, distribution

or redistribution on two conditions: One, that some form of copyright

notice is included in every copy distributed or copied, showing the

copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com

..The second condition is that the material is not to be used for any purpose

contrary to the purposes and objectives of this site. This permission does

not extend to materials on this site which are copyrighted by others.